Table 2.

The Results for the Relationship Between ATB Use and PFS of Immune Checkpoint Inhibitors in NSCLC.

	N	Hazard ration (HR)	P for HR	Heterogeneity (P, I2)	Publication bias
Progression-free survival
Overall	13	1.41 [1.23-1.61]	0.000	0.003, 60.3%	Begg’s Test = 0.462 Egger’s test = 0.366
Time of antibiotics use
A group [−60, 0]	5	1.53 [1.22-1.92]	0.000	0.024, 64.3%	Begg’s Test = 1.000 Egger’s test =/
B group [−30, 0 ]	2	1.55 [1.14-2.10]	0.005	0.041, 76.0%	Begg’s Test =/ Egger’s test =/
C group [−60,30]	5	1.34 [1.06-1.70]	0.014	0.001, 77.4%	Begg’s Test = 0.602 Egger’s test =/
D group [−30,30]	3	1.54 [1.14-2.06]	0.005	0.004, 82%	Begg’s Test = 1.000 Egger’s test =/
E group [0 , 30 ]	3	1.63 [1.12-2.369]	0.010	0.154, 46.6%	Begg’s Test =/ Egger’s test =/
F group [During]	5	1.20 [0.99-1.45]	0.067	0.021, 65.5%	Begg’s Test =/ Egger’s test =/
ICI drug
PD-1 inhibitor	5	1.73 [1.25-2.40]	0.001	0.241, 31.20%	Begg’s Test = 1.000 Egger’s test =/
PD-1/PD-L1/CTLA-4 inhibitor	8	1.35 [1.16-1.57]	0.000	0.002, 68.9%	Begg’s Test = 1.000 Egger’s test = 0.408
Sample size
<100	6	1.91 [1.43-2.56]	0.000	0.190, 32.8%	Begg’s Test = 1.000 Egger’s test = 0.695
≥100	7	1.29 [1.11-1.51]	0.001	0.008, 65.4%	Begg’s Test = 1.000 Egger’s test =/
Country
Asia	3	2.64 [1.77-3.92]	0.000	0.721, 0.0%	Begg’s Test = 0.296 Egger’s test = 0.146
No-Asia	8	1.29 [1.12-3.92]	0.000	0.028, 51.8%	Begg’s Test = 1.000 Egger’s test = 0.891